Once dismissed as a party drug, MDMA is reemerging as a therapeutic option for treatment-resistant PTSD. Dr. Kenji Hashimoto explores MDMA’s neurobiological, gut–brain and vagus nerve effects while ...

(Reuters) - Combining intensive psychotherapy with a pure form of the party drug ecstasy is safe and could aid recovery in people with post-traumatic stress disorder (PTSD), according to the findings ...

With mental health needs at an all-time high, and uncertainty across politics and research, its launch introduces a hub for evidence-based psychedelic care-supporting New Yorkers while advancing ...

MDMA-assisted psychotherapy is demonstrating to be promising for PTSD. Source: Activedia/Pixabay, Creative Commons In recent years, MDMA-assisted psychotherapy has been highlighted as a breakthrough ...

The Food and Drug Administration (FDA) declined on Friday to approve MDMA-assisted psychotherapy as a treatment for post-traumatic stress disorder (PTSD). The agency has asked Lykos Therapeutics, ...

Credit: Getty Images. Significant factors limit MDMA’s ability to be used in the treatment of post-traumatic stress disorder. Significant factors limit MDMA’s ability to be used in the treatment of ...

A decades-long campaign to legalize MDMA as a mainstream medical treatment will reach a climax as soon as Friday, with the Food and Drug Administration poised to decide whether the psychedelic should ...

We’re honored to welcome Bruce Sewick, LCPC, CADC, a nationally respected educator and clinician, for a powerful presentation on MDMA-assisted psychotherapy and its transformative potential for ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." On Friday, the Food and Drug Administration (FDA) refused to approve midomafetamine (MDMA) for the ...

When the Food and Drug Administration (FDA) declined to approve MDMA-assisted psychotherapy as a treatment for post-traumatic stress disorder (PTSD) last year, the details of its objections were not ...

Efforts to make MDMA legally available as a psychotherapeutic catalyst hit a daunting roadblock in August. The Food and Drug Administration (FDA) declined to approve a new drug application submitted ...

Lykos Therapeutics, the drug’s manufacturer, said the agency requested an additional phase 3 clinical trial to study the drug’s safety and efficacy, according to an Aug. 9 news release from the ...